Lutein-Loaded, Biotin-Decorated Polymeric Nanoparticles Enhance Lutein Uptake in Retinal Cells
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Age related macular degeneration (AMD) is one of the leading causes of visual loss and is responsible for approximately 9% of global blindness. It is a progressive eye disorder seen in elderly people (>65 years) mainly affecting the macula. Lutein, a carotenoid, is an antioxidant, and has shown neuroprotective properties in the retina. However, lutein has poor bioavailability owing to poor aqueous solubility. Drug delivery to the posterior segment of the eye is challenging due to the blood–retina barrier. Retinal pigment epithelium (RPE) expresses the sodium-dependent multivitamin transporter (SMVT) transport system which selectively uptakes biotin by active transport. In this study, we aimed to enhance lutein uptake into retinal cells using PLGA–PEG–biotin nanoparticles. Lutein loaded polymeric nanoparticles were prepared using O/W solvent-evaporation method. Particle size and zeta potential (ZP) were determined using Malvern Zetasizer. Other characterizations included differential scanning calorimetry, FTIR, and in-vitro release studies. In-vitro uptake and cytotoxicity studies were conducted in ARPE-19 cells using flow cytometry and confocal microscopy. Lutein was successfully encapsulated into PLGA and PLGA–PEG–biotin nanoparticles (<250 nm) with uniform size distribution and high ZP. The entrapment efficiency of lutein was ≈56% and ≈75% for lutein-loaded PLGA and PLGA–PEG–biotin nanoparticles, respectively. FTIR and DSC confirmed encapsulation of lutein into nanoparticles. Cellular uptake studies in ARPE-19 cells confirmed a higher uptake of lutein with PLGA–PEG–biotin nanoparticles compared to PLGA nanoparticles and lutein alone. In vitro cytotoxicity results confirmed that the nanoparticles were safe, effective, and non-toxic. Findings from this study suggest that lutein-loaded PLGA–PEG–biotin nanoparticles can be potentially used for treatment of AMD for higher lutein uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Age-related macular degeneration
de Jong, P. T. V. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062326 · Cited by 787
Topical formulation of self-assembled antiviral prodrug nanomicelles for targeted retinal delivery
Mandal, A., Cholkar, K., Khurana, V., Shah, A., Agrahari, V., Bisht, R., Pal, D., & Mitra, A. K. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00128 · Cited by 60 · cited 1×
“FITC labelling was performed according to a previously reported protocol with slight modifications [47].”
Method
Cited by
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery
Jurczyk, M., Jelonek, K., Musiał-Kulik, M., Beberok, A., Wrześniok, D., & Kasperczyk, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030326 · Cited by 133
Self-assembling tacrolimus nanomicelles for retinal drug delivery
Gote, V., Mandal, A., Alshamrani, M., & Pal, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111072 · Cited by 39
“The final solution of FITC-labelled TAC-NMF and TAC was aliquoted and stored at −20◦C until further use, as described in [29,33,34].”
MethodSelf-citationXu, J.-F., Wang, Y.-P., & Liu, X.-H. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.06.019 · Cited by 12
Ansari, M., Gupta, C., Kulkarni, Y. A., & Singh, K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125235 · Cited by 10
Metadata
- Authors
- Bolla, P. K., Gote, V., Singh, M., Patel, M., Clark, B. A., & Renukuntla, J.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-08-24
- Volume
- 12
- Issue
- 9
- Pages
- 798
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3080856888
- Cited by
- 71
- References
- 4
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.